wire - news in brief

« BACK

Economics/Business



Results 301 - 350 of 415.


Economics / Business - 25.09.2015
A rail expert for the Executive Board
A rail expert for the Executive Board
The ETH Board has announced its new Vice President for Human Resources and Infrastructure at ETH Zurich: Ulrich Alois Weidmann.

Health - Economics / Business - 24.09.2015
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and bre

Economics / Business - Environment - 11.09.2015
For the 7th year running, Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Indices
For the 7th year running, Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Indices For the seventh consecutive year, Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry.

Innovation - Economics / Business - 28.08.2015
Thinking outside the box
Thinking outside the box
Design Thinking is an innovation method that puts people centre stage when developing new ideas. For the first time, ETH Zurich is offering master's students in any field a course on this approach to innovation.

Pharmacology - Economics / Business - 21.07.2015
Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
Sales , core operating income and core EPS grew (cc ) for continuing operations in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3 billion (-28%,

Pharmacology - Economics / Business - 23.04.2015
Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio
Continuing operations saw sales, core operating income and core EPS grow (cc ) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc) Operating income was USD 2.8 billion (-1%, +15% cc) Cor

Pharmacology - Economics / Business - 02.03.2015
Novartis announces completion of transactions with GSK
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on

Economics / Business - Pharmacology - 27.02.2015
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Shareholders approve 18 th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Director

Pharmacology - Economics / Business - 27.01.2015
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
Net sales grew in FY 2014, with strong core margin expansion Net sales increased 1% (+3% cc ) to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7 b

Economics / Business - 01.01.2015
Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion
Novartis announced today that it has completed effective January 1, 2015 the divestment of its Animal Health Division to Eli Lilly and Company (Lilly) for approximately USD 5.4 billion.

Economics / Business - Pharmacology - 28.10.2014
Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter
Net sales up 4% (+5% cc) in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc ) in Q3 Strong operating income growth in Q3 of 14% (+18% cc) Core

Economics / Business - Pharmacology - 26.10.2014
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza seg

Health - Economics / Business - 09.10.2014
New data on the global economic impact and burden of preventable blindness and vision impairment highlighted for World Sight Day
Annual economic impact equals more than 350,000 healthy life years lost and over €20 billion EUR as a result of blindness for 14 countries studied Screening for diabetic retinopathy, cataracts and AM

Economics / Business - 08.10.2014
Changes to the Novartis Executive Committee after expected completion of portfolio transactions
Three members of the Executive Committee of Novartis to leave company, following completion of portfolio transactions expected to close in first half 2015 Basel, October 8, 2014 - Novartis confirmed

Physics - Economics / Business - 18.09.2014
CERN and APS announce partnership for Open Access
Geneva, 18 September 2014. The American Physical Society (APS) and The European Organization for Nuclear Research (CERN ) jointly announce a partnership to make all CERN-authored articles published in the APS journal collection to be Open Access.

Economics / Business - Innovation - 21.08.2014
«Europe is very much about stakeholders, Silicon Valley about shareholders»
Michael Dillhyon is a US entrepreneur and investor living in Zug. Originally, he moved to Switzerland and only wanted to accompany the exit of a US spin-off company.

Pharmacology - Economics / Business - 17.07.2014
Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook
Net sales grew 2% in Q2, with core operating leverage across Q2 and H1 Net sales of USD 14.6 billion grew 2% (+2% cc ) in Q2; USD 28.7 billion (+2%, +2% cc) in H1 Strong operating income

Economics / Business - Health - 09.07.2014
Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting standard, increasing transparency
2013 Corporate Responsibility (CR) Performance Report builds on a long history of CR and reporting Report uses new Global Reporting Initiative G4 guidelines, one year ahead of required implementation

Innovation - Economics / Business - 26.06.2014

Innovation - Economics / Business - 14.05.2014
"With Only 5 Million, We Have Developed a Competitive Mini-Projector"
Lemoptix is developing an ultra-compact projector. The EPFL spin-off has already successfully entered a very competitive market, and will target new markets in 2014.

Economics / Business - Pharmacology - 24.04.2014
Novartis delivered solid sales and profit growth in the first quarter of 2014
Net sales of USD 14.0 billion up 1% (+3% cc ) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating income

Economics / Business - Pharmacology - 22.04.2014
Novartis announces portfolio transformation
Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines Novarti

Pharmacology - Economics / Business - 09.04.2014
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014.

Environment - Economics / Business - 28.03.2014
Working together for a better food supply
ETH Zurich has received CHF 5 million from the Coop Sustainability Fund to undertake research projects in the field of sustainable food production over the next several years.

Economics / Business - Pharmacology - 25.02.2014
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Economics / Business - Pharmacology - 29.01.2014
Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Campus - Economics / Business - 27.01.2014

Pharmacology - Economics / Business - 27.01.2014
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Economics / Business - 27.11.2013
Peering into the future: How cities grow
Peering into the future: How cities grow
How cities will grow in the future depends on fundamental laws, which have been uncovered by EPFL researchers. Migration patterns into and out of cities are the result of millions of individual decisions, which in turn are affected by thousands of factors like economics, location, politics, security, aesthetics, sentiments and others.

Pharmacology - Economics / Business - 22.11.2013
Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
Novartis takes action to strengthen portfolio and capital allocation, starts share buyback Blood transfusion diagnostics unit divested as part of ongoing portfolio management Reiterates optimal capit

Economics / Business - Pharmacology - 22.10.2013
Novartis delivers strong sales performance in third quarter driven by growth products’ momentum; innovation newsflow reinforces growth prospects
Group net sales up 4% (+6% cc ) to USD 14.3 billion in third quarter and up 2% (+4% cc) in first nine months; all divisions contributed to growth Negative currency impact of 6 percentage points

Economics / Business - Pharmacology - 17.07.2013
Novartis delivered growth across all divisions in second quarter (cc); raises guidance for full year 2013
Group net sales increased 1% (+3% cc ) versus year ago to USD 14.5 billion in second quarter, up 2% (+4% cc) to USD 28.5 billion in first half Core operating income was USD 3.8 b

Pharmacology - Economics / Business - 24.04.2013
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extension for Ex

Economics / Business - 14.03.2013

Economics / Business - Health - 22.02.2013
Shareholders approve all resolutions proposed by Novartis Board of Directors - Dr. Joerg Reinhardt to succeed as Chairman following transition period
Shareholders approve 16 th consecutive dividend increase to CHF 2.30 (+2%) per share for 2012, representing a payout of approximately 65% of net income from continuing operations New compensat

Economics / Business - 19.02.2013
Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders
Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Dr. Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional compensation.

Innovation - Economics / Business - 24.09.2012
Nexthink, EPFL spin-off
Pedro Bados, co-founder of Nexthink, EPFL spin-off, dreams of making the region a breeding ground for start-ups.

Health - Economics / Business - 19.07.2012
Novartis second quarter results enhance future growth prospects with eight significant regulatory milestones; on track to deliver 2012 outlook
Group net sales increased 1% in constant currencies (cc), with growth in recently launched products more than offsetting loss from Diovan patent expiration Core operating income of USD 3.9 bil

Innovation - Economics / Business - 04.06.2012
CERN adopts new scheme for easy access to intellectual property
CERN adopts new scheme for easy access to intellectual property Geneva, 4 June 2012.

Economics / Business - 30.05.2012